{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:00:05Z","timestamp":1790910005829,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.neuropharm.2012.06.013","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T12:08:30Z","timestamp":1340798910000},"page":"215-223","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey"],"prefix":"10.1016","volume":"64","author":[{"given":"Sean M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Uslaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Huszar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Vardigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donnie","family":"Eddins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Toolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kandebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzat T.","family":"Raheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Schreier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Breslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Renger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.013_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1076\/jhin.11.3.265.10391","article-title":"Historical development of the dopamine hypothesis of schizophrenia","volume":"11","author":"Baumeister","year":"2002","journal-title":"J.\u00a0Hist. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","article-title":"Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance","volume":"47","author":"Boess","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib4","series-title":"Alkoxy Tetrahydro-Pyridopryimidine PDE10 Inhibitors","author":"Breslin","year":"2010"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib5","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1476-5381.2011.01524.x","article-title":"GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses","volume":"164","author":"Bruno","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1046\/j.1471-4159.2002.00877.x","article-title":"D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures","volume":"81","author":"Chao","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1023870821631","article-title":"Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms","volume":"13","author":"Cirillo","year":"2003","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib10","first-page":"112","article-title":"Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)","volume":"110","author":"Delay","year":"1952","journal-title":"Ann. Med. Psychol. (Paris)"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1037\/0735-7044.103.3.526","article-title":"Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants","volume":"103","author":"Diamond","year":"1989","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/380069a0","article-title":"Dissociation in prefrontal cortex of affective and attentional shifts","volume":"380","author":"Dias","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib13","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.107.043786","article-title":"Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs","volume":"73","author":"Fumagalli","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/jnp.6.4.348","article-title":"Working memory dysfunction in schizophrenia","volume":"6","author":"Goldman-Rakic","year":"1994","journal-title":"J.\u00a0Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0896-6273(00)80798-9","article-title":"Beyond the dopamine receptor: the DARPP-32\/protein phosphatase-1 cascade","volume":"23","author":"Greengard","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v65n0312","article-title":"Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness","volume":"65","author":"Harvey","year":"2004","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/108705710200700305","article-title":"A\u00a0fluorescence polarization assay for cyclic nucleotide phosphodiesterases","volume":"7","author":"Huang","year":"2002","journal-title":"J.\u00a0Biomol. Screen."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuropharm.2011.05.009","volume":"61","author":"Hutson","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0006-3223(00)00926-4","article-title":"Object retrieval\/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity","volume":"48","author":"Jentsch","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2004.09.004","article-title":"NIMH-MATRICS survey on assessment of neurocognition in schizophrenia","volume":"72","author":"Kern","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1523\/JNEUROSCI.5236-10.2011","article-title":"Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling","volume":"31","author":"Li","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","article-title":"Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase","volume":"234","author":"Loughney","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: the future path for animal models","volume":"34","author":"Markou","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib30","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib31","doi-asserted-by":"crossref","unstructured":"Millan, M.J., Agid, Y., Brune, M., Bullmore, E.T., Carter, C.S., Clayton, N.S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., Dubois, B., Geyer, M.A., Goodwin, G.M., Gorwood, P., Jay, T.M., Joels, M., Mansuy, I.M., Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington, M., Young, L.J., 2012. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11, 141\u2013168.","DOI":"10.1038\/nrd3628"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1535-5535(04)00281-3","article-title":"Automation of in\u00a0vitro dose-inhibition assays utilizing the tecan genesis and as integrated software package to support the drug discovery process","volume":"8","author":"Mosser","year":"2003","journal-title":"J.\u00a0Assoc. Lab. Automation"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnana.2011.00043","article-title":"Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons","volume":"5","author":"Nishi","year":"2011","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.10R01FM","article-title":"Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission","volume":"114","author":"Nishi","year":"2010","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1471-4159.2010.06604.x","article-title":"Basal ganglia pathology in schizophrenia: dopamine connections and anomalies","volume":"113","author":"Perez-Costas","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib36","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib37","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","article-title":"Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats","volume":"62","author":"Rodefer","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib40","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.72.11.4376","article-title":"Brain receptors for antipsychotic drugs and dopamine: direct binding assays","volume":"72","author":"Seeman","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev.cellbio.23.090506.123516","article-title":"The cell biology of synaptic plasticity: AMPA receptor trafficking","volume":"23","author":"Shepherd","year":"2007","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A\u00a0possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib45","series-title":"Characterization of a Novel Small Molecule Phosphodiesterase 10 (PDE10A) Inhibitor","author":"Smith","year":"2011"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib46","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1523\/JNEUROSCI.20-12-04480.2000","article-title":"Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in\u00a0vivo","volume":"20","author":"Snyder","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib47","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0079-6123(08)62645-X","article-title":"Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys","volume":"82","author":"Taylor","year":"1990","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib49","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1037\/0735-7044.104.4.564","article-title":"Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier","volume":"104","author":"Taylor","year":"1990","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib50","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2011.05.013","article-title":"The evolution of antipsychotic switch and polypharmacy in natural practice \u2013 a longitudinal perspective","volume":"130","author":"Tsutsumi","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib53","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002130000466","article-title":"Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats","volume":"150","author":"Wadenberg","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib55","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1523\/JNEUROSCI.19-03-01142.1999","article-title":"Different contributions of the hippocampus and perirhinal cortex to recognition memory","volume":"19","author":"Wan","year":"1999","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.013_bib56","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4522(97)00075-4","article-title":"Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys","volume":"80","author":"Wilkinson","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib57","series-title":"Cyclic Nucleotide Phosphodiesterases in Health and Disease","first-page":"377","article-title":"Role of A-kinase anchoring proteins in the compartmentation in cyclic nucleotide signaling","author":"Witczak","year":"2007"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.013_bib59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol. Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T05:38:57Z","timestamp":1561873137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":59,"alternative-id":["S0028390812002717"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.013","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}